Optimark(gadoversetamide)
Optimark (gadoversetamide) is a small molecule pharmaceutical. Gadoversetamide was first approved as Optimark on 1999-12-08. It has been approved in Europe to treat magnetic resonance imaging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| diagnosis | D003933 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | 2 | 1 | 2 | 6 | |
| Magnetic resonance imaging | D008279 | — | — | — | 2 | 2 | 4 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | 1 | 1 | 3 |
| Breast diseases | D001941 | N60-N65 | 1 | — | — | 1 | — | 2 | |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | 1 | 1 | 2 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | 1 | 2 | |
| Lymphatic metastasis | D008207 | EFO_1001364 | — | — | — | 1 | 1 | 2 | |
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | 1 | |
| Nephrogenic fibrosing dermopathy | D054989 | EFO_1001814 | — | — | — | 1 | — | 1 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | C67 | 1 | 1 | 1 | — | 1 | 3 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 1 | — | — | 3 |
| Cerebral arterial diseases | D002539 | EFO_1000859 | — | — | 2 | — | — | 2 | |
| Prostatectomy | D011468 | — | — | 1 | — | — | 1 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | — | 1 | — | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | 1 | — | — | 1 |
| Renal artery obstruction | D012078 | EFO_1001150 | N28.0 | — | — | 1 | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | 1 | ||
| Aortic aneurysm | D001014 | EFO_0001666 | I71.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uterine cervical neoplasms | D002583 | 2 | 2 | — | — | — | 2 | ||
| Hip fractures | D006620 | EFO_0003964 | S72.00 | 1 | 1 | — | — | — | 2 |
| Local anesthesia | D000772 | 1 | 1 | — | — | — | 2 | ||
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | 1 | 1 | — | — | — | 1 |
| Postoperative pain | D010149 | G89.18 | — | 1 | — | — | — | 1 | |
| Renal cell carcinoma | D002292 | 1 | 1 | — | — | — | 1 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | 1 | — | — | — | 1 | |
| Small cell carcinoma | D018288 | 1 | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | 1 | — | — | — | 1 | ||
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.89 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | 1 | — | — | — | — | 1 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | 1 | ||
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
| Aortic dissection | D000784 | I71.0 | — | — | — | — | 1 | 1 | |
| Aortic diseases | D001018 | — | — | — | — | 1 | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GADOVERSETAMIDE |
| INN | gadoversetamide |
| Description | Gadoversetamide is a gadolinium coordination entity that consists of Gd(3+) coordinated to 3,6,9-triazaundecadiamide in which each of the amide nitrogens is substituted by a 2-methoxyethyl group and in which the nitrogens at positions 3, 6, and 9 are each substituted by carboxylatomethyl group. The gadolinium is coordinated to the three tertiary amino groups as well as to the carboxylate groups. A white odourless powder that is freely soluble in water, gadoversetamide has paramagnetic properties and is used as a contrast agent in magnetic resonance imaging. It distributes mainly in extracellular fluid, but does not cross the blood-brain barrier. It is used particularly in imaging the brain, spine and liver. It has a role as a MRI contrast agent. |
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3] |
Identifiers
| PDB | — |
| CAS-ID | 131069-91-5 |
| RxCUI | 228833 |
| ChEMBL ID | CHEMBL1200457 |
| ChEBI ID | 31644 |
| PubChem CID | 444013 |
| DrugBank | DB00538 |
| UNII ID | RLM74T3Z9D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 427 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,316 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more